Kctech: Sharp Share Price Rise Alongside Improving Margins, With Valuation Well Above Last Year-End

Thesis

The data supports an earnings improvement story. Trailing revenue of ₩476.5B is well above 2025 revenue of ₩382.9B, and operating income of ₩94.9B compares with ₩60.0B for 2025. Returns and margins have moved up, and the balance sheet looks conservative, with liabilities at 14.1% of equity.

The data does not explain why results improved, and no news headlines are available. The share price gain (67.0% in one month, 26.0% in three months) has been larger than the profit gain, so the multiple has expanded. Investor flow, foreign ownership and short balance data are not available, so we cannot say who has been buying.

Business overview

Kctech is listed on KOSPI and classified in the data under medical and precision devices. It was founded on 2017-11-01 and listed on 2017-12-05, with 20,690,323 listed shares. Market capitalization is about ₩2.3T. It has two co-CEOs, 양호근 and 최동규.

Revenue history from filings: ₩344.5B in 2021, ₩378.2B in 2022, ₩286.9B in 2023 (down 24.1%), ₩385.4B in 2024 (up 34.3%) and ₩382.9B in 2025 (down 0.7%). Revenue has therefore been cyclical rather than steadily rising. The data does not describe products or customers.

Financial analysis

Figures come from filed financial statements (DART). For the twelve months to H1 2026, revenue was ₩476.5B, operating income ₩94.9B and net income ₩87.3B. Operating margin was 19.9% and net margin 18.3%, with ROE at 16.5%.

By comparison, 2025 operating margin was 15.7% and ROE 10.6%. Earlier operating margins were 12.9% in 2024, 11.4% in 2023, 16.0% in 2022 and 15.1% in 2021. The current margin is the highest in the period shown.

Liabilities to equity is 14.1%. Cash is ₩35.2B and free cash flow is ₩18.1B, which is much lower than net income of ₩87.3B. Borrowings data is not available.

Valuation

Current multiples are a P/E of 26.9, P/B of 4.1, P/S of 4.9 and EV/EBITDA of 20.8. The dividend yield is 0.4%. Enterprise value is about ₩2.3T.

At the end of 2025 the P/E was 15.4 and the P/B 1.5, so both have risen sharply. Year-end multiples for earlier years are not available.

Among the listed peers, only TSE has multiples in the data, with a P/E of 32.6 and P/B of 7.2, above Kctech on both. Park Systems, Classys, DI and Curiox Biosystems have no multiples in the data, so a wider peer comparison is not possible.

Catalysts

• A major sales or supply contract was filed on 2026-08-12, though the data does not give its size or terms.
• Preliminary consolidated earnings on 2026-08-05 and the half-year report on 2026-08-13 confirmed the stronger trailing results.
• A 5%+ holding report was filed on 2026-10-02, following several others in March and April, which points to changes among large shareholders.
• A change in the largest shareholder's holdings was filed on 2026-03-25.

Risks

• The P/E has risen from 15.4 at the end of 2025 to 26.9, so the valuation depends more on profits continuing to grow.
• Revenue has swung widely, with a 24.1% fall in 2023 and a 34.3% rise in 2024, showing cyclicality.
• Free cash flow of ₩18.1B is well below net income of ₩87.3B, so profit is not fully converting to cash in the latest period.
• The share price is up 67.0% in one month and trades at ₩113,400 against a 52-week low of ₩35,100, which leaves room for sharp reversals.
• Investor flows, foreign ownership and short interest are not available, so positioning risk cannot be assessed.

Closing view

The filings show a clear improvement in revenue, margins and returns, and a low-debt balance sheet. The share price has moved faster than earnings, lifting the P/E from 15.4 to 26.9, and cash conversion is weaker than profit. With no news, flow data or contract details, the reasons for the rally and its durability cannot be determined from this data alone.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Report history

1. Oct 13, 2026InitiationKctech: Sharp Share Price Rise Alongside Improving Margins, With Valuation Well Above Last Year-End